Get to know our clinical trials

Clinical trial with MRTX849 in monotherapy and in combination with pembrolizumab in patients with advanced non-small cell lung cancer with KRAS G12C mutation.

THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY OF MRTX849 IN MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB ADMINISTERED IN A FIRST-LINE TREATMENT SETTING TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A SPECIFIC MODIFICATION IN TUMOR GENES (KRAS G12C MUTATION).

Status
In recruitment
headquarters
Multisede

Technical Summary

  • PHASE 2 STUDY OF MRTX849 IN MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION. IMMUNOTHERAPY.
  • Code EudraCT: 2020-003101-58
  • Protocol number: 849-007
  • Promoter: Mirati
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.